AGC Inc.

AGC is a Tokyo-based materials group that grew out of Japan's first flat-glass producer into a five-segment portfolio spanning architectural glass, automotive glass, electronics, chemicals and life science. It reported FY2025 net sales of JPY 2,058.8 billion and operating profit of JPY 127.5 billion. Management runs an "ambidextrous" model: mature, asset-heavy core businesses (float glass, automotive glazing, display substrates, chlor-alkali) are expected to generate cash, while four strategic businesses (mobility, electronics materials, performance chemicals and life science CDMO) are expected to deliver growth. The company claims leading global shares in automotive glass, ETFE fluoropolymer and car-mounted cover glass, and number-two positions in TFT glass substrates and EUV mask blanks. Its problem is returns. ROE has been below 5% in each of the last four years after impairments of roughly JPY 125 billion in display (2022) and in biopharmaceutical CDMO (2024), and the stock trades at about 0.67 times book. The current agenda is ROCE repair, lower capital expenditure and a semiconductor-materials build-out.

What the company does. AGC manufactures and sells glass, electronic materials, chemicals and ceramics, and provides contract development and manufacturing (CDMO) services for pharmaceuticals and agrochemicals. Glass remains the largest activity: the group operates 26 float lines worldwide (two through an equity affiliate) and automotive glass plants on five continents. The Chemicals segment is the largest single reporting segment by revenue (28% of FY2025 sales) and the second-largest profit contributor after... more precisely, it was the largest profit contributor in FY2025 at JPY 53.0 billion, ahead of Electronics at JPY 47.5 billion (Financial Review 2025).

The company's own description. AGC frames its mission as being "an everyday essential part of our world" through unique materials and solutions (Group Philosophy "Look Beyond", revised January 2025; Financial Review 2025). Since 2016 it has divided the portfolio into core businesses and strategic businesses, and in 2021 it adopted the long-term strategy Vision 2030, which targets a portfolio that is resilient to market swings and high in asset efficiency, growth and carbon efficiency.

Independent characterisation. AGC is best understood as three different economic engines under one balance sheet:

1. Cyclical, capital-intensive commodity businesses. Float glass in Europe, Asia and Brazil, and chlor-alkali/PVC in Southeast Asia. Earnings follow construction activity, energy costs, and caustic soda and PVC spreads. These businesses hold a large share of operating assets and currently earn sub-10% ROCE.

2. Engineered-product businesses tied to OEM cycles. Automotive glass and display glass substrates. Both went through heavy restructuring between 2020 and 2025; Automotive reached ROCE above 10% before common-cost allocation in FY2025, and Display is targeted to reach 10% in 2027.

3. Differentiated materials and services. Semiconductor materials (EUV mask blanks, CMP slurry, synthetic quartz, SiC parts), optoelectronics, fluorochemicals, and CDMO. These earn the group's highest returns (Electronics and Integrated Chemicals) and its worst (Life Science, loss-making since FY2023).

Revenue model. Almost all revenue is product sales to industrial customers. The service element is the CDMO business (Life Science, 6.5% of FY2025 sales), which earns fees for process development and batch manufacturing under project and multi-year contracts. Licensing and subscription revenue are not separately disclosed and are immaterial. The split between product and service revenue is not publicly disclosed beyond the segment figures.

Value-chain position. AGC is an upstream and midstream materials supplier. It melts and forms glass, runs salt electrolysis and fluorine chemistry from raw salt and fluorite, and sells into fabricators, tier-one suppliers, OEMs, panel makers, chipmakers and pharmaceutical companies. In architectural glass it also has downstream processing and distribution in Japan and Europe.

Customer types and end markets. Construction and renovation (window glass, Low-E, PVC), automotive OEMs and replacement glass distributors, display panel makers, semiconductor device and equipment makers, smartphone camera supply chains, chemical, pulp, alumina and nickel refiners (caustic soda), and pharmaceutical, biotech and agrochemical companies. Customer concentration figures are not publicly disclosed.

Sources: Financial Review 2025; AGC Data Book; FY2025 results presentation (6 Feb 2026).

Strategic architecture. Three layers sit on top of each other: the Group Philosophy "Look Beyond" (revised January 2025), the long-term strategy Vision 2030 (announced February 2021), and the medium-term plan AGC plus-2026 (February 2024, covering FY2024–FY2026).

AGC plus-2026 pillars (as named by the company)

1. Evolution of the ambidextrous strategy: strengthen cash generation in core businesses, revise the scope of strategic businesses, explore next-generation areas.

2. Deepening of sustainability management: redefine social value into three themes (Blue planet, Innovation, Well-being) and set sustainability KPIs alongside financial KPIs.

3. Promotion of value-creation DX: digital plus manufacturing capability, and supply-chain streamlining.

4. Strengthening of the management foundation: group governance, human capital management, alignment of business strategy with the technology platform.

Financial targets and their erosion

The operating profit target has been cut by 35% in two steps. Management attributes the cuts to slowdowns in China and Europe, the Life Science volume shortfall, lower-than-planned EUV blank and optoelectronics sales, and weak Southeast Asian chlor-alkali prices. The Vision 2030 targets (operating profit of JPY 300 billion or more, strategic business operating profit of JPY 190 billion or more, ROE of 10% or more) are formally maintained. The company states its cost of equity at about 7% and WACC at about 5% (2023–2025 average, CAPM), and aims for ROE above 8% "as soon as possible from 2027".

ROCE programme. Group ROCE of 10% (equivalent to 8% ROE) is the operating target. Levers are value-based pricing, cost reduction through stable production (a group-wide cost project led by the CFO), higher added value, tighter investment selection, inventory reduction, and sale or exit of businesses. Business-level goals: Automotive to 15% ROCE within a few years; Display to 10% in 2027; Life Science to profitability in 2027.

Initiatives announced in the last 24 months

Sustainability commitments. Net zero Scope 1 and 2 by 2050; 30% reduction in Scope 1 and 2 by 2030 against 2019; 30% reduction in Scope 3 categories 1, 10, 11 and 12 by 2030; suppliers representing 30% of Scope 3 categories 1 and 3 to hold science-based targets by 2027.

Shareholder returns. Stable dividends at about 3% dividend on equity; FY2026 dividend held at JPY 210; policy review considered from 2027 depending on recovery. Buybacks are judged case by case.

FY2026 guidance (unchanged at Q1 and H1). Net sales JPY 2,200 billion (+6.9%), operating profit JPY 150 billion (+17.7%), profit before tax JPY 124 billion, profit attributable to owners JPY 77 billion (EPS JPY 363.12), ROE 5.2%. Assumptions: JPY 155 per US dollar, JPY 180 per euro; Dubai crude raised from USD 70 to USD 100 per barrel in May 2026.

Sources: Financial Review 2025; FY2024 and FY2025 results presentations; Q2 FY2026 earnings call; Nikkei Asia (5 May 2026).

Pricing is not publicly disclosed for any product line; sales are negotiated business-to-business. Launch years are given where the company discloses them.

Architectural Glass

Automotive

Electronics — Display

Electronics — Electronic Materials

Chemicals — Essential Chemicals

Chemicals — Performance Chemicals

Life Science

The Yokohama facility will run four 2,000-litre and two 5,000-litre single-use bioreactors (18,000 litres). The Colorado sites (Boulder and Longmont) were closed in 2025 and a divestiture is being negotiated.

Ceramics/Other

Sources: AGC Data Book (product information sections); FY2025 results presentation; AGC news release (8 Dec 2025); AGC Biologics release (28 Jul 2026).

All figures are IFRS, fiscal years ending 31 December. EBITDA follows the company definition (operating profit plus depreciation and amortisation).

Income statement

Margins and growth

Revenue CAGR was 4.9% over FY2021–FY2025 (four years) and 7.8% over FY2020–FY2025 (five years, from JPY 1,412.3 billion), analyst calc.

Balance sheet

Cash flow

Ratios

Notes on the ratio table:

• ROIC is analyst-calculated as operating profit less a notional 30% tax, divided by year-end interest-bearing debt plus total equity. Company ROCE is operating profit over year-end operating assets and is disclosed at group level only for FY2023–FY2025.

• Interest coverage is operating profit over interest expense (S&P). The cash conversion cycle uses year-end receivables, inventories and payables (S&P) against sales and cost of sales.

• S&P shows a FY2021 dividend of JPY 160; the company's eleven-year summary shows JPY 210, which includes a special dividend. The company figure is used.

• S&P's "operating income" (for example JPY 129.0 billion in FY2025) differs from company operating profit (JPY 127.5 billion) because the company measure includes equity-method income. Company figures are used.

Commentary on trends and inflections

Revenue: Sales stepped up by about 20% in each of FY2021 and FY2022, driven by European glass price inflation, PVC and caustic soda prices, and yen depreciation. They have been flat at about JPY 2.0–2.1 trillion since. FY2025 sales fell 0.4%: automotive pricing and performance chemicals gains were offset by lower PVC prices, weaker EUV blank shipments and lower Asian glass prices (Financial Review 2025).

Profitability: Gross margin fell six points between FY2021 and FY2023 as energy and raw material costs rose and commodity chemical spreads normalised, and has recovered only half a point since. Operating profit has been stuck in a JPY 126–129 billion band for three years, about 38% below the FY2021 peak. Management acknowledges that operating profit missed the initial plan in four consecutive years (FY2025 results presentation, page 44).

Below the line: Two large non-cash charges explain the two loss years. FY2022 included asset write-downs of about JPY 128 billion, mainly in Display. FY2024 included impairments of JPY 124.8 billion, of which JPY 118.3 billion related to biopharmaceutical CDMO (goodwill JPY 60.6 billion in Denmark, Italy and the US; fixed and intangible assets JPY 57.7 billion in the US), plus a JPY 36.0 billion loss on the sale of the Russian subsidiaries (FY2024 results presentation, page 7). FY2025 other expenses fell to JPY 30.7 billion, including JPY 9.7 billion of impairments and JPY 10.2 billion of restructuring.

Balance sheet: Leverage is moderate: debt to equity of 0.37 times against a ceiling of 0.5. But cash has halved since FY2022 to JPY 94.7 billion while property, plant and equipment grew by JPY 300 billion, reflecting eight consecutive years of capex above JPY 200 billion. Net debt to EBITDA rose from 1.1 to 1.8 times. Goodwill halved in FY2024 on the CDMO write-off. Non-controlling interests of JPY 246.6 billion are large, mainly from Southeast Asian chemical and glass subsidiaries.

Cash flow: Operating cash flow has been steady at JPY 210–330 billion. After capex, free cash flow was negligible in FY2022 and FY2023 and covered the dividend (about JPY 45 billion) only in FY2025. The FY2023 buyback of JPY 50 billion was effectively debt-funded. Management now says the large expansion round finished in 2025 and guides FY2026 capex down to JPY 190 billion.

Interest coverage: Coverage fell from 32 times to about 7–9 times as interest expense more than doubled with higher overseas rates.

FY2026 year to date

H1 FY2026 sales rose JPY 105.1 billion (about 10.6% on analyst arithmetic; one aggregator reports 9.5%), helped by yen depreciation, the Thai chlor-alkali expansion and pricing. Operating cash flow was about JPY 104.9 billion, derived from reported investing outflow of JPY 94.8 billion and free cash flow of JPY 10.1 billion (the transcript text shows 194.9, which does not reconcile). Total assets were JPY 3,006.3 billion and debt to equity 0.38 times.

Sources: Financial Review 2025 (eleven-year summary, MD&A, financial statements); FY2024 and FY2025 results presentations; StockAnalysis.com (S&P Global Market Intelligence) income statement, balance sheet and cash flow pages; Q2 FY2026 earnings call transcript (Investing.com, 4 Aug 2026); H1 FY2025 kessan tanshin (1 Aug 2025).

Management guidance for FY2026 (unchanged since February 2026)

Segment forecast for FY2026 (net sales / operating profit, JPY billion). Architectural Glass 480 / 20; Automotive 510 / 32; Electronics 360 / 45; Chemicals 680 / 56; Life Science 160 / -5; Ceramics/Other 60 / 2.

Progress. H1 operating profit of JPY 64.7 billion is 43% of the full-year forecast, in line with the company's usual second-half weighting. Chemicals reached 50% of its full-year profit forecast in H1 (JPY 28.2 billion); Electronics (JPY 18.7 billion, 42%) and Automotive (JPY 13.3 billion, 42%) need a stronger second half; Life Science lost JPY 6.1 billion against a full-year forecast loss of JPY 5 billion, so the forecast depends on a profitable fourth quarter.

Consensus expectations. Net income of about JPY 80 billion in FY2026 and JPY 98 billion in FY2027 (MarketScreener), implying the market expects guidance to be met and ROE to approach 6–6.5% in FY2027, still below the 8% goal.

Bull case

1. Semiconductor materials compound. EUV blank volumes in 2026 already exceed 2025, management expects 2027 sales to pass the 2024 peak, and capacity for three product lines grows 20–50% by 2028. Electronics and Integrated Chemicals already earn the group's highest ROCE.

2. Free cash flow inflects. Capex falls by about JPY 61 billion in FY2026 after eight years above JPY 200 billion while the Thai expansion and Copenhagen capacity start to earn. With debt to equity at 0.38 times, a 2027 return-policy review could bring buybacks at 0.67 times book.

3. Loss-makers stop bleeding. Life Science swinging from a JPY 22.3 billion loss to break-even would by itself lift operating profit by about 17%. The Yokohama contract and Colorado closure make that path more visible.

Bear case

1. Targets keep slipping. Four consecutive years of missed plans and a 35% cut to the FY2026 target suggest structural over-optimism. H1 strength was partly currency and a one-time consolidation effect that management declined to quantify.

2. Commodity and energy exposure. Crude at USD 100 against a USD 70 budget, volatile PVC spreads dependent on Chinese export tax policy, and European energy costs can erase pricing gains. Automotive and Electronics profits fell year on year in H1 on manufacturing costs.

3. Capital is still trapped in low-return assets. Architectural Glass, Essential Chemicals-SEA and Life Science hold roughly half of operating assets at low or negative ROCE; PFAS liabilities and a possible further AGC Biologics impairment are unquantified.

Catalysts and monitorables for the next 12 months

Analyst verdict. AGC is a high-quality materials franchise wrapped in a low-return conglomerate. The evidence for quality is real: leading or number-two global positions in automotive glass, display substrates, EUV mask blanks and ETFE, an investment-grade balance sheet, and operating cash flow that has not fallen below JPY 210 billion in five years. The evidence for low returns is equally clear: ROE under 5% for four years, about JPY 250 billion of impairments across display and biologics, and a medium-term profit target that has been cut by more than a third. The market's response, a 0.67 times book multiple and a "Hold" consensus, is rational.

What has changed in 2026 is the direction of capital. For the first time since 2018, capex is falling sharply, exits are being executed rather than discussed (polycarbonate, coatings, the Saudi JV, Dragontrail, Colorado, the hydrogen membrane plant), and incremental investment is concentrated in semiconductor materials where AGC already earns its best returns. The first half delivered a 20% rise in operating profit and a narrower Life Science loss, and the Yokohama contract gives the biologics recovery an anchor.

The case is not yet proven. Guidance was held rather than raised despite a strong half, costs are rising in automotive and electronics, and energy prices are well above budget. Management's own framing, that three businesses are moving from recovery to resilience while two are still in recovery, is an honest description of a group midway through repair.

On balance, AGC offers a 3.7% yield and asset backing while investors wait for ROCE to move from 5.6% toward 10%. The February 2027 plan, and whether it pairs credible targets with a firmer return policy, is the decision point. Until then the shares look fairly valued with a positive skew if Life Science reaches break-even and semiconductor volumes track the plan.

Data limitations.

Group headcount fell by 791 in FY2025.